Respiratory syncytial virus (RSV) is increasingly being recognized as an important cause of disease in older adults worldwide. Its impact is estimated to be comparable to or even greater than that of influenza. However, RSV is not typically tested for, as there is no specific treatment. A successful vaccine would represent a vital breakthrough, deeply benefiting this growing segment of the population.
To that end, a double-blind phase 1 study was conducted with subjects 60 years of age and older. The subjects received vaccines containing escalating doses of soluble RSV fusion protein(sF) alone or adjuvanted with glucopyranosyl lipid A, a toll-like receptor-4 agonist, in 2% stable emulsion (GLA-SE). The full report of the study with its conclusions can be read in here.
One of the authors of this key study is Craig Curtis, MD, CPI, and Chief Medical Officer at Bioclinica. Dr. Curtis is a Florida-licensed physician with Board Certification in Family Medicine. He has over 15 years of clinical trial experience covering all phases of research and numerous therapeutic areas. He has served as Principal Investigator on over 200 trials in the areas of general medicine, psychiatry, neurology, analgesia, and early clinical development.
Dr. Curtis is a member of the Association of Clinical Research Professionals (ACRP), the Drug Information Association (DIA), and the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He earned his medical degree from Northeastern Ohio University College of Medicine.
Read the study now:
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-likereceptor-4 agonist and stable emulsion adjuvant